Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Alpha-glucosidase inhibitors from Seikagaku Kogyo

June 21, 1996

Pediatric clinical trials for Remune commence

June 14, 1996

GR-92754: Most effective DHFR inhibitor

June 14, 1996

Alferon LDO enters clinical trials

June 14, 1996

Additional AIDS gene therapy phase II trial

June 14, 1996

Rescriptor available through Canadian expanded access program

June 14, 1996

GS-840 enters phase II/III

June 14, 1996

Sankyo reports anti-HIV-1 oligodeoxyribonucleotides

June 14, 1996

Immunostimulating whole plant product undergoes clinical trials on AIDS patients

June 7, 1996

NSC-158393: Promising candidate for development as anti-AIDS drug

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...